AbbVie Inc. Long-Lived Assets
AbbVie Inc. (ABBV) had Long-Lived Assets of $5.63 billion as of 2025-12-31, per its 10-K filed 2026-02-20.
Financial Statements › Notes › Segment Reporting
us-gaap:NoncurrentAssets · last filed 2026-02-20
- 2025-12-31: Long-Lived Assets $5.63B.
- 2024-12-31: Long-Lived Assets $5.13B.
- 2023-12-31: Long-Lived Assets $4.99B.
- 2022-12-31: Long-Lived Assets $4.93B.
| Period end | Long-Lived Assets | Long-Lived Assets as first filed |
|---|---|---|
| 2025-12-31 | $5.63B 10-K · filed 2026-02-20 | |
| 2024-12-31 | $5.13B 10-K · filed 2026-02-20 | |
| 2023-12-31 | $4.99B 10-K · filed 2025-02-14 | |
| 2022-12-31 | $4.93B 10-K · filed 2024-02-20 | |
| 2021-12-31 | $5.11B 10-K · filed 2023-02-17 | |
| 2020-12-31 | $5.25B 10-K · filed 2022-02-18 | |
| 2019-12-31 | $2.96B 10-K · filed 2021-02-19 | |
| 2018-12-31 | $2.88B 10-K · filed 2020-02-21 | |
| 2017-12-31 | $2.80B 10-K · filed 2019-02-27 | |
| 2016-12-31 | $2.60B 10-K · filed 2018-02-16 | |
| 2015-12-31 | $2.56B 10-K · filed 2017-02-17 | $2.60B 10-K · filed 2016-02-19 |
| 2014-12-31 | $2.50B 10-K · filed 2016-02-19 | |
| 2013-12-31 | $2.30B 10-K · filed 2015-02-20 | |
| 2012-12-31 | $2.20B 10-K · filed 2014-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |